Page last updated: 2024-08-24

etofibrate and Coronary Disease

etofibrate has been researched along with Coronary Disease in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Caramelli, B; Mansur, AP; Ramires, JA; Serrano, CV; Spósito, AC	1
Maranhão, RC; Ramires, JA; Santos, RD; Spósito, AC; Vinagre, CG	1
Fenselau, S; Schrezenmeir, J; Steinmetz, A	1

Reviews

1 review(s) available for etofibrate and Coronary Disease

Article	Year
Treatment of dyslipoproteinemia in the metabolic syndrome. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2001, Volume: 109, Issue:4 Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome	2001

Article

Year

Treatment of dyslipoproteinemia in the metabolic syndrome.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2001, Volume: 109, Issue:4

Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome

2001

Trials

2 trial(s) available for etofibrate and Coronary Disease

Article	Year
Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl. The American journal of cardiology, 1999, Jan-01, Volume: 83, Issue:1 Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease; Delayed-Action Preparations; Drug Administration Schedule; Drug Synergism; Female; Humans; Lipids; Male; Middle Aged; Niacin; Time Factors; Treatment Outcome	1999
Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis, 2001, Feb-01, Volume: 154, Issue:2 Topics: Anticholesteremic Agents; Biomarkers; Cholesterol; Cholesterol, HDL; Chylomicrons; Clofibric Acid; Coronary Disease; Cross-Over Studies; Double-Blind Method; Drug Interactions; Emulsions; Female; Humans; Injections, Intravenous; Lipolysis; Male; Middle Aged; Prognosis; Triglycerides	2001

Article

Year

Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl.

The American journal of cardiology, 1999, Jan-01, Volume: 83, Issue:1

Topics: Anticholesteremic Agents; Cholesterol, HDL; Clofibric Acid; Coronary Disease; Delayed-Action Preparations; Drug Administration Schedule; Drug Synergism; Female; Humans; Lipids; Male; Middle Aged; Niacin; Time Factors; Treatment Outcome

1999

Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.

Atherosclerosis, 2001, Feb-01, Volume: 154, Issue:2

Topics: Anticholesteremic Agents; Biomarkers; Cholesterol; Cholesterol, HDL; Chylomicrons; Clofibric Acid; Coronary Disease; Cross-Over Studies; Double-Blind Method; Drug Interactions; Emulsions; Female; Humans; Injections, Intravenous; Lipolysis; Male; Middle Aged; Prognosis; Triglycerides

2001